内皮祖细胞在老年缺血性心脏病血管新生治疗中的研究进展  

Research progress of endothelial progenitor cells therapy for therapeutic angiogenesis in the elderly with ischemic heart disease

作　　者：王坤[1] 单圣帅 刘承云[1] 

机构地区：[1]武汉华中科技大学同济医学院附属协和医院老年病科,430022

出　　处：《中华老年医学杂志》2017年第9期1049-1053,共5页Chinese Journal of Geriatrics

基　　金：国家自然科学基金（81370468）

摘　　要：缺血性心脏病（IHD）严重威胁着老年人的身体健康，促进缺血心肌区域血管新生、改善微循环成为防治IHD的新策略。内皮祖细胞（EPC）在出生后的血管新生和血管内皮损伤后的修复中起重要作用，已成为治疗性血管新生领域的研究热点。高龄与心血管风险可降低EPC的数量和损害其功能，现总结老年IHD患者体内EPC的特点及EPC治疗的研究进展，为临床治疗提供依据。Ischemic heart disease （IHD） is a serious threat to health of the elderly, and endothelial progenitor cells therapy-induced therapeutic angiogenesis can improve vascular reperfusion and functional recovery in isehemic myocardium. Endothelial progenitor cell （EPC） therapy plays an important role in endothelial repair and postnatal angiogenesis. And the concept of EPC therapy has reeeived attention. EPC population is decreased in numbers and in functional activity, which are correlated with age and cardiovascular risk factor. And patients with these backgrounds have less therapeutic benefit. In this review, we will focus on overview of the latest research progressions of characteristic of EPC in the elderly with IHD, and on current studies of EPC-based angiogenesis therapies for providing theoretical basis in the promising clinical treatment.

关 键 词：内皮细胞 衰老 心肌缺血 

分 类 号：R54[医药卫生—心血管疾病]